<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">NCP</journal-id>
<journal-id journal-id-type="hwp">spncp</journal-id>
<journal-id journal-id-type="nlm-ta">Nutr Clin Pract</journal-id>
<journal-title>Nutrition in Clinical Practice</journal-title>
<issn pub-type="ppub">0884-5336</issn>
<issn pub-type="epub">1941-2452</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0884533613491787</article-id>
<article-id pub-id-type="publisher-id">10.1177_0884533613491787</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Nutrition Management of Infants With Surgical Short Bowel Syndrome and Intestinal Failure</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Cole</surname><given-names>Conrad R.</given-names></name>
<degrees>MD, MPH, MSc</degrees>
<xref ref-type="aff" rid="aff1-0884533613491787">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kocoshis</surname><given-names>Samuel A.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0884533613491787">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0884533613491787"><label>1</label>Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio</aff>
<author-notes>
<corresp id="corresp1-0884533613491787">Conrad R. Cole, MD, MPH, MSc, Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, MLC 2010, Cincinnati, OH 45229, USA. Email: <email>conrad.cole@cchmc.org</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>4</issue>
<fpage>421</fpage>
<lpage>428</lpage>
<permissions>
<copyright-statement>© 2013 American Society for Parenteral and Enteral Nutrition</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">The American Society for Parenteral and Enteral Nutrition</copyright-holder>
</permissions>
<abstract>
<p>Appropriate nutrition recommendations are important for the successful management of the infant with an injured gastrointestinal tract postsurgery who is at risk for intestinal failure. Management strategies that can be used to augment successful adaptation and prevent liver disease are summarized in this review. These include appropriate postoperative fluid and electrolyte management, modification of parenteral nutrition to minimize intestinal failure–associated liver disease, early and aggressive enteral feeding advancement, the use of hormonal and trophic agents, prevention of central line–associated bloodstream infections using ethanol lock, appropriate treatment, and prevention of pathologic small bowel bacterial overgrowth.</p>
</abstract>
<kwd-group>
<kwd>Pediatrics</kwd>
<kwd>nutrition</kwd>
<kwd>enteral nutrition</kwd>
<kwd>parenteral nutrition</kwd>
<kwd>gastroenterology</kwd>
<kwd>short bowel syndrome</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Nutrition therapy following significant gut injury from surgery or as a result of a congenital disorder or dysmotility is usually complex and requires close attention to detail. The ultimate goal of management is enteral autonomy. Depending on the type of injury, recovery and adaptation of the gut can be fast (over a couple of days) or quite prolonged (years).<sup><xref ref-type="bibr" rid="bibr1-0884533613491787">1</xref></sup> If the patient is dependent on parenteral nutrition (PN) for &gt;4 weeks, that patient’s intestinal dysfunction is operationally defined as intestinal failure.<sup><xref ref-type="bibr" rid="bibr2-0884533613491787">2</xref></sup> The goal of this review is to provide an update on the acute and long-term nutrition management of the infant with significant surgical resection of the intestines who is at risk for intestinal failure.</p>
<p>In infants, intestinal failure is usually a complication arising from significant injury to the gastrointestinal (GI) tract. The resultant functional intestinal mass may fall below the minimum required to maintain adequate nutrition and fluid balance needed for normal growth and development.<sup><xref ref-type="bibr" rid="bibr3-0884533613491787">3</xref>,<xref ref-type="bibr" rid="bibr4-0884533613491787">4</xref></sup> The duration of PN and the need for intestinal rehabilitation make the management of these children challenging. The outcome of these children is significantly improved if they are managed by a multidisciplinary team that allows for fully integrated care of inpatients and outpatients with intestinal failure by fostering coordination of surgical, medical, and nutrition management.<sup><xref ref-type="bibr" rid="bibr5-0884533613491787">5</xref></sup></p>
<p>Necrotizing enterocolitis (NEC) is still the most common indication for surgery that leads to short bowel syndrome (SBS) and subsequently intestinal failure.<sup><xref ref-type="bibr" rid="bibr6-0884533613491787">6</xref>,<xref ref-type="bibr" rid="bibr7-0884533613491787">7</xref></sup> Gastroschisis and its accompanying motility disorder are now identified as the second most common cause of intestinal failure.<sup><xref ref-type="bibr" rid="bibr7-0884533613491787">7</xref>,<xref ref-type="bibr" rid="bibr8-0884533613491787">8</xref></sup> Although infants with gastroschisis might not have undergone bowel resection, they can develop some degree of intolerance to enteral nutrition (EN) and so are dependent on PN for a variable time after repair or closure of the abdominal wall defect. Absolute remnant intestinal length following resection is not the best predictor of weaning from PN despite early reports suggesting otherwise.<sup><xref ref-type="bibr" rid="bibr9-0884533613491787">9</xref></sup> The quality of the remnant bowel is now considered significant, as is the use of proven strategies to augment adaptation and prevent complications associated with prolonged PN. The healthcare costs for infants with intestinal failure are very high and estimated to average $505,000 in the first year and about $300,000 in subsequent years.<sup><xref ref-type="bibr" rid="bibr10-0884533613491787">10</xref></sup> The difference in cost between the first year and subsequent years is attributed to the length of initial hospitalization and frequent repeat hospitalizations.</p>
<p>The factors that determine how well an infant does after the initial surgery include (1) age at the time of the surgery, (2) site and amount of bowel resected, (3) function (absorption and motility) of the remnant bowel, (4) adaptive capacity of the remnant bowel, (5) injury to the bowel (due to infections, bacterial overgrowth, ischemia, stricture), and (6) whether complications associated with chronic PN (liver disease, recurrent line infections, and loss of vascular access) occur.</p>
<sec id="section1-0884533613491787">
<title>Initial Phase of Management</title>
<p>In the immediate postoperative phase, fluid and electrolyte management as well as nutrition care is dependent on the use of PN. Postoperatively, there is usually ileus, which can last from 48 hours to up to a week depending on the degree of injury and the primary disease. This period can be associated with high gastric output followed by increased jejunostomy/ileostomy output or profuse diarrhea. During this phase, if the fluid and electrolyte resuscitation is not appropriately managed, the patient can become dehydrated and experience electrolyte abnormalities. Fluid resuscitation involves the use of maintenance volumes based on the weight of the patient and fluid replacement based on fluid losses. Fluid replacement is usually 1 mL for every mL of fluid loss initially. Replacement fluid is determined by the volume lost from ostomies, fistulas, or drainage tubes (gastric, jejunum, ileum, or colon).</p>
<p>Transient gastric acid hypersecretion and hypergastrinemia have been reported in these patients in response to the injury and resection.<sup><xref ref-type="bibr" rid="bibr11-0884533613491787">11</xref></sup> This is more significant in patients with more than two-thirds of their estimated bowel resected. These patients should be managed in the immediate postoperative period with intravenous (IV) proton pump inhibitors or H2 blockers.<sup><xref ref-type="bibr" rid="bibr12-0884533613491787">12</xref></sup> Gastric acid hypersecretion leads to further malabsorption because the acidic environment inactivates pancreatic enzymes and precipitates bile acid. This further damages the epithelium of the proximal small bowel and stimulates motility. The use of acid-reducing medication should be temporally around the postoperative period and in the immediate period around starting enteral feeds as the hypergastrinemia is transient. However, this therapy can be continued in patients with significant gastroesophageal reflux.</p>
</sec>
<sec id="section2-0884533613491787">
<title>Modification of PN</title>
<p>Patients receiving prolonged PN due to intestinal failure are at increased risk for developing PN-associated cholestasis (PNAC). This is defined as a direct bilirubin level &gt;2 mg/dL along with elevated transaminases and γ-glutamyl transferase after at least 2 weeks of PN in an infant who does not have a primary liver disease.<sup><xref ref-type="bibr" rid="bibr13-0884533613491787">13</xref></sup> The specific cause of PNAC is unknown, but most researchers and clinicians hypothesize that PNAC is as a result of a combination of factors, including the composition of the PN, central line–associated bloodstream infections (CLA-BSIs), and lack of enteral feeds. In patients with surgical SBS and other forms of intestinal failure, PNAC is referred to as intestinal failure–associated liver disease (IFALD).</p>
<p>Although excesses in any of the macronutrients (glucose, protein, and lipid) have been found noxious to the liver, the single parenteral nutrient most closely associated with cholestasis and subsequent end-stage liver disease is lipid. The type and amount of lipid administered in patients with intestinal failure have been identified as factors associated with severe IFALD.<sup><xref ref-type="bibr" rid="bibr14-0884533613491787">14</xref>,<xref ref-type="bibr" rid="bibr15-0884533613491787">15</xref></sup> Patients who received soy-based lipid infusions &gt;1 g/kg body weight for long periods are at increased risk for developing IFALD.<sup><xref ref-type="bibr" rid="bibr14-0884533613491787">14</xref>,<xref ref-type="bibr" rid="bibr16-0884533613491787">16</xref></sup> Published reports of the use of a fish oil–based investigational lipid emulsion to treat IFALD have lent credence to this theory. Confounding these findings is the fact that with the use of fish oil–based lipids, the investigators also markedly decreased lipids to 1 g/kg/d compared with the 3-g/kg/d dose of soy-based lipid emulsion in the control historic group of patients.<sup><xref ref-type="bibr" rid="bibr15-0884533613491787">15</xref>,<xref ref-type="bibr" rid="bibr17-0884533613491787">17</xref></sup> This has led to the use of a lipid minimization strategy among intestinal rehabilitation programs in North America. One center has shown in a prospective study that lipid minimization with 1 g/kg/d twice a week is associated with decreased PNAC and reversal of cholestasis.<sup><xref ref-type="bibr" rid="bibr18-0884533613491787">18</xref></sup> Although in this study, essential fatty acid deficiency was documented, there was no difference in the growths (weights and lengths) between the patients who had lipid minimization compared with the control group. To prevent essential fatty acid deficiency, patients should receive an average of &gt;0.5 g/kg/d of lipid, and serum evaluation of essential fatty acids should be done periodically. Our practice is to limit the lipid dose to 1 g/kg/d in infants likely to develop IFALD and those with PNAC who are going to continue receiving long-term PN.</p>
<p>The attention regarding the potential impact of the type of lipid was stimulated by the investigational use of fish oil–based lipid solutions in North America.<sup><xref ref-type="bibr" rid="bibr15-0884533613491787">15</xref>,<xref ref-type="bibr" rid="bibr17-0884533613491787">17</xref></sup> The constituents of the major IV lipid infusions are summarized in <xref ref-type="table" rid="table1-0884533613491787">Table 1</xref>. These differences might account for the different rates of developing liver disease in patients receiving long-term PN. Fish oil–based lipid solutions are available only at specific institutions in North America under an investigational new drug evaluation with approval from institutional review boards and are restricted to children with IFALD. These products have being approved for use in Europe. There is a need to evaluate the safety and long-term effects of lipid minimization and use of lipid alternatives on patients with regard to long-term growth, neurodevelopment, and hepatic fibrosis.</p>
<table-wrap id="table1-0884533613491787" position="float">
<label>Table 1.</label>
<caption>
<p>Comparison of the Constituents of Major IV Fat Emulsions.</p>
</caption>
<graphic alternate-form-of="table1-0884533613491787" xlink:href="10.1177_0884533613491787-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Fatty Acid</th>
<th align="center">Soy-Based IV Fat Emulsion<sup><xref ref-type="table-fn" rid="table-fn2-0884533613491787">a</xref></sup></th>
<th align="center">Fish Oil–Based IV Fat Emulsion<sup><xref ref-type="table-fn" rid="table-fn3-0884533613491787">b</xref></sup></th>
<th align="center">Soy-, MCT-, Olive Oil–, Fish Oil–Based IV Fat Emulsion<sup><xref ref-type="table-fn" rid="table-fn4-0884533613491787">c</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>α-Tocopherol, mg/L</td>
<td>38</td>
<td>150–296</td>
<td>200</td>
</tr>
<tr>
<td>Phytosterols, mg/L</td>
<td>348</td>
<td>0</td>
<td>47.6</td>
</tr>
<tr>
<td>Linoleic, g/100 mL</td>
<td>5</td>
<td>0.1–0.7</td>
<td>2.9</td>
</tr>
<tr>
<td>α-Linolenic, g/100 mL</td>
<td>0.9</td>
<td>&lt;0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>EPA, g/100 mL</td>
<td>0</td>
<td>1.28–2.82</td>
<td>0.3</td>
</tr>
<tr>
<td>DHA, g/100 mL</td>
<td>0</td>
<td>1.44–3.09</td>
<td>0.05</td>
</tr>
<tr>
<td>Oleic, g/100 mL</td>
<td>2.6</td>
<td>0.6–1.3</td>
<td>2.8</td>
</tr>
<tr>
<td>Palmitic, g/100 mL</td>
<td>1</td>
<td>0.25–1</td>
<td>0.9</td>
</tr>
<tr>
<td>Stearic, g/100 mL</td>
<td>0.35</td>
<td>0.05–0.2</td>
<td>0.3</td>
</tr>
<tr>
<td>Arachidonic, g/100 mL</td>
<td>0</td>
<td>0.1–0.4</td>
<td>0.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0884533613491787">
<p>DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; IV, intravenous; MCT, medium-chain triglyceride.</p>
</fn>
<fn id="table-fn2-0884533613491787">
<label>a</label>
<p>Intralipid (Baxter Healthcare Corporation, Deerfield, IL).</p>
</fn>
<fn id="table-fn3-0884533613491787">
<label>b</label>
<p>Omegaven (Fresenius Kabi, Bad Homburg, Germany).</p>
</fn>
<fn id="table-fn4-0884533613491787">
<label>c</label>
<p>SMOF lipid (Fresenius Kabi).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>With the use of lipid minimization, excessive glucose infusions rates (GIRs) are being used in these children, which can lead to hepatic steatosis. The American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.); the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition; and the American Academy of Pediatrics guidelines for infants and young children recommend limiting the GIR at 12–14 mg/kg/min.<sup><xref ref-type="bibr" rid="bibr19-0884533613491787">19</xref>,<xref ref-type="bibr" rid="bibr20-0884533613491787">20</xref></sup> It is important that these guidelines are followed if at all possible. However, it may be impossible to stay within these guidelines for GIRs to account for calories lost from lipid minimization. Patients needing higher GIRs should be monitored for hyperglycemia and liver disease periodically.</p>
</sec>
<sec id="section3-0884533613491787">
<title>Enteral Nutrition</title>
<p>The most important strategy for stimulating intestinal rehabilitation is EN. In neonates, continuous enteral tube feeding, beginning with breast milk or an amino acid–based formula, should be added as soon as postoperative ileus resolves.<sup><xref ref-type="bibr" rid="bibr21-0884533613491787">21</xref>,<xref ref-type="bibr" rid="bibr22-0884533613491787">22</xref></sup> When breast milk is not available, one of the amino acid formulas should be used as they have been shown to be effective in decreasing the duration of PN.<sup><xref ref-type="bibr" rid="bibr21-0884533613491787">21</xref>,<xref ref-type="bibr" rid="bibr23-0884533613491787">23</xref></sup> Although long-chain triglycerides (LCTs) are a major trophic factor for intestinal adaptation in SBS, they are not well absorbed in the small intestines and require micelle formation.<sup><xref ref-type="bibr" rid="bibr13-0884533613491787">13</xref>,<xref ref-type="bibr" rid="bibr24-0884533613491787">24</xref></sup> A combination of medium-chain triglycerides (MCTs) and LCTs (ratio of MCTs to LCTs of 30%:70%) has been shown to be the optimal combination of fat source for absorption in patients with significant intestinal resection, with or without colon in continuity.<sup><xref ref-type="bibr" rid="bibr25-0884533613491787">25</xref></sup> Feeds should be gradually increased in volume and supplemented by small oral meals. Continuous enteral feeds are better tolerated compared with intermittent bolus feeds.<sup><xref ref-type="bibr" rid="bibr26-0884533613491787">26</xref></sup> This permits the continuous saturation of carrier proteins.<sup><xref ref-type="bibr" rid="bibr27-0884533613491787">27</xref>,<xref ref-type="bibr" rid="bibr28-0884533613491787">28</xref></sup> As the volume of enteral feeds is increased, PN should be decreased isocalorically (calorie for calorie, not volume for volume). Enteral feeding is important for protecting against cholestatic liver disease.<sup><xref ref-type="bibr" rid="bibr29-0884533613491787">29</xref></sup></p>
<p>Bolus oral feedings in small quantities, 3–4 times a day (equal or less than the volume tolerated continuously per hour), and the timely introduction of solid feeds at the same developmental age as healthy infants will allow the child to swallow and chew appropriately. Feeding therapy is usually required as these infants are likely to have some degree of oral aversion due to delayed introduction of oral feeds as a result of prematurity, prolonged intubation, and cardiovascular instability.</p>
<p>These patients tend to have a relative lactase deficiency and tolerate complex carbohydrates rather than simple sugars. Advancement of enteral feeds is based on several factors, including stool output, vomiting, and irritability. An increase in stool output that is &gt;50% is usually a contraindication to increasing enteral feeds. If stool output is between 30 and 40 mL/kg body weight, then the increase should be accomplished cautiously. An output &gt;40 mL/kg body weight is a relative contraindication to increasing enteral feeds.<sup><xref ref-type="bibr" rid="bibr30-0884533613491787">30</xref></sup> Patients without a colon tolerate diets that are high in fat (30%–40% of caloric intake) better, whereas those with intact colons experience steatorrhea, magnesium, and calcium loss with high-fat intake. With calcium loss, oxalate absorption is enhanced in the colon and kidneys, which can lead to the formation of oxalate renal stones.<sup><xref ref-type="bibr" rid="bibr31-0884533613491787">31</xref>,<xref ref-type="bibr" rid="bibr32-0884533613491787">32</xref></sup> Hence, it is necessary to restrict oxalate intake in SBS patients with a colon to decrease the risk of oxalate renal stones. Oral calcium supplements can also reduce the formation of oxalate stones.</p>
<p>Cycling of PN is the next step as enteral feeds are tolerated. When EN constitutes 20% or more of total nutrition intake, the duration of PN should be reduced if the child’s serum glucose level can be adequately maintained by continuous enteral infusion.<sup><xref ref-type="bibr" rid="bibr33-0884533613491787">33</xref></sup> As soon as sufficient stability is reached, the child should be discharged home under continued outpatient care with a team experienced in intestinal rehabilitation.</p>
<p>The main long-term problems comprise bacterial overgrowth, fluid and electrolyte abnormalities, nutrition deficiencies, PN-related liver disease, and central venous line complications such as sepsis and thrombosis.<sup><xref ref-type="bibr" rid="bibr34-0884533613491787">34</xref></sup> Aggressive laboratory monitoring of patients while they receive PN and during the transition to full EN, as shown in <xref ref-type="table" rid="table2-0884533613491787">Table 2</xref>, is required to prevent nutrition deficiencies and electrolyte disturbances. After successfully weaning off PN, these patients need to continue to have frequent laboratory monitoring to prevent the development of essential micronutrient deficiencies.</p>
<table-wrap id="table2-0884533613491787" position="float">
<label>Table 2.</label>
<caption>
<p>Laboratory Monitoring for Patients Receiving Parenteral Nutrition (PN).</p>
</caption>
<graphic alternate-form-of="table2-0884533613491787" xlink:href="10.1177_0884533613491787-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Laboratory Test</th>
<th align="center">Initial</th>
<th align="center">With Every Change in PN</th>
<th align="center">Weekly Until Stable</th>
<th align="center">Long Term/Home</th>
<th align="center">Indications</th>
<th align="center">Charge<sup><xref ref-type="table-fn" rid="table-fn5-0884533613491787">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>PN profile (renal, calcium, phosphate, magnesium, liver panel, total protein, serum albumin, triglyceride, bile acid, prealbumin, random glucose)</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes, then per MD discretion</td>
<td>Per MD discretion</td>
<td/>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$$$</xref></td>
</tr>
<tr>
<td>Complete blood count with differential</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes, then per MD discretion</td>
<td>Monthly/as indicated</td>
<td>Monitor anemia</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$</xref></td>
</tr>
<tr>
<td>Urine electrolytes</td>
<td>Yes</td>
<td/>
<td>Weekly until stable</td>
<td>Monthly</td>
<td>Dehydration, poor weight/length gain</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$$</xref></td>
</tr>
<tr>
<td>Urine-specific gravity</td>
<td>Yes</td>
<td/>
<td>Weekly until stable, then at MD discretion</td>
<td>As indicated</td>
<td>Dehydration; after decrease in intravenous volume administered; input/output not monitored</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$</xref></td>
</tr>
<tr>
<td>Prothrombin time/international normalized ratio</td>
<td/>
<td/>
<td/>
<td>If indicated, first level should occur after 1 mo on PN and then every 2–4 wk</td>
<td>Liver disease/cholestasis/gastrointestinal bleed</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$</xref></td>
</tr>
<tr>
<td>25-OH vitamin D</td>
<td/>
<td/>
<td/>
<td>First level should occur after 3 mo on PN and then every 6 mo</td>
<td>Patient with low serum 25-OH levels on therapy</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$$</xref></td>
</tr>
<tr>
<td/>
<td/>
<td/>
<td/>
<td>If indicated, every 3 mo</td>
<td/>
<td/>
</tr>
<tr>
<td>Red blood cell folate</td>
<td/>
<td/>
<td/>
<td>Every 6 mo</td>
<td/>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$</xref></td>
</tr>
<tr>
<td>Iron/total iron-binding capacity/ferritin</td>
<td/>
<td/>
<td/>
<td>Every 3 mo<break/>If indicated, every 1 mo</td>
<td>Anemia with microcytosis and patient on enteral or parenteral iron</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$$</xref></td>
</tr>
<tr>
<td>Ceruloplasmin and copper</td>
<td/>
<td/>
<td/>
<td>If indicated, after 30 days of PN, then every 2 mo</td>
<td>Cholestasis, persistent anemia</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$</xref></td>
</tr>
<tr>
<td>Zinc and selenium</td>
<td/>
<td/>
<td/>
<td>If indicated, first level should occur after 6 mo on PN or if high ostomy output, after 30 days, and then every 3–6 mo</td>
<td>Patients with chronic diarrhea, high ostomy output</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$</xref></td>
</tr>
<tr>
<td>Vitamins A, E, and K</td>
<td/>
<td/>
<td/>
<td>First level should occur after 6 mo on PN and then every 6 mo</td>
<td>Cholestasis</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$$</xref></td>
</tr>
<tr>
<td>α-Fetoprotein</td>
<td/>
<td/>
<td/>
<td>Every 12 mo</td>
<td>Liver cirrhosis or chronic liver disease</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$</xref></td>
</tr>
<tr>
<td>Chromium</td>
<td/>
<td/>
<td/>
<td>If indicated</td>
<td>Glycemic control difficult despite glucose infusions rate &lt;15</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$</xref></td>
</tr>
<tr>
<td>Triene/tetraene ratio</td>
<td/>
<td/>
<td/>
<td>If indicated</td>
<td>Total fat intake (enteral and parenteral fat) &lt;0.5 g/kg for &lt;5 d</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$$</xref></td>
</tr>
<tr>
<td>D-lactate</td>
<td/>
<td/>
<td/>
<td>If indicated</td>
<td>Encephalopathy or anion-gap metabolic acidosis</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$$</xref></td>
</tr>
<tr>
<td>Manganese</td>
<td/>
<td/>
<td/>
<td>If indicated, every 3 mo</td>
<td>Patient is cholestatic</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$</xref></td>
</tr>
<tr>
<td>Urine methylmalonic acid</td>
<td/>
<td/>
<td/>
<td>If indicated, first level at a year, then every 12 mo</td>
<td>Ileal resection, macrocytic anemia</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$$</xref></td>
</tr>
<tr>
<td>Serum B<sub>12</sub></td>
<td/>
<td/>
<td/>
<td>If indicated, first level at a year, then every 12 mo</td>
<td>Ileal resection, macrocytic anemia</td>
<td><xref ref-type="table-fn" rid="table-fn5-0884533613491787">$$</xref></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0884533613491787">
<label>a</label>
<p>$, &lt;$100; $$, $100–200; $$$, &gt;$200. Based on current charges.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-0884533613491787">
<title>Hormonal and Trophic Agents</title>
<p>Growth hormone (GH) administration studies in animal models showed enhanced mucosal hyperplasia and increased water, sodium, and amino acid absorption.<sup><xref ref-type="bibr" rid="bibr35-0884533613491787">35</xref><xref ref-type="bibr" rid="bibr36-0884533613491787"/>-<xref ref-type="bibr" rid="bibr37-0884533613491787">37</xref></sup> Pediatric and adult studies initially produced contradictory results regarding the impact of GH on tolerance of EN.<sup><xref ref-type="bibr" rid="bibr35-0884533613491787">35</xref>,<xref ref-type="bibr" rid="bibr38-0884533613491787">38</xref><xref ref-type="bibr" rid="bibr39-0884533613491787"/>-<xref ref-type="bibr" rid="bibr40-0884533613491787">40</xref></sup> In a double-blind randomized controlled trial involving 41 adult patients with SBS, GH (0.1 mg/kg/d for 4 weeks) reduced PN volume by approximately 2 L/wk in addition to the reduction achieved with standard therapy.<sup><xref ref-type="bibr" rid="bibr41-0884533613491787">41</xref></sup> The benefits associated with this therapy lasted almost 4 months following completion of the therapy. Increase in body weight, lean body mass, and fat-free mass was also documented using a lower dose of GH (0.5 IU/kg/d or 0.024 mg/kg/d).<sup><xref ref-type="bibr" rid="bibr42-0884533613491787">42</xref></sup> Based on these data, GH therapy is approved by the U.S. Food and Drug Administration (FDA) for the treatment of PN-dependent SBS only in adult patients.</p>
<p>Glucagon-like peptide 2 (GLP-2) is produced by the intestinal mucosal L cells in the ileum and proximal colon and pancreatic A cells. Postprandial serum GLP-2 is decreased in patients with extensive small bowel resection,<sup><xref ref-type="bibr" rid="bibr43-0884533613491787">43</xref></sup> and the level best correlates with residual small intestinal length.<sup><xref ref-type="bibr" rid="bibr44-0884533613491787">44</xref></sup> Exogenous GLP-2 has a significant trophic effect on the intestine and appears to stimulate enterocyte proliferation while reducing rates of enterocyte apoptosis.<sup><xref ref-type="bibr" rid="bibr45-0884533613491787">45</xref></sup> GLP-2 appears to act via the highly localized expression of GLP-2 receptor in the intestinal epithelium.<sup><xref ref-type="bibr" rid="bibr46-0884533613491787">46</xref></sup> Teduglutide, a novel recombinant analogue of the human GLP-2, differs from GLP-2 in the substitution of alanine by glycine at the second position at the N-terminus. The single amino acid substitution relative to naturally occurring GLP-2 results in resistance to in vivo degradation by the enzyme dipeptidyl peptidase-IV (DPP-IV). Adult trials have shown decreased PN dependence in adults with SBS.<sup><xref ref-type="bibr" rid="bibr47-0884533613491787">47</xref>,<xref ref-type="bibr" rid="bibr48-0884533613491787">48</xref></sup> There is currently no pediatric study evaluating the effectiveness and safety of long-term use of GLP-2/teduglutide. Teduglutide is the most recently approved drug for use in adults with intestinal failure due to SBS.</p>
<p>Glutamine, a nonessential amino acid that is a primary energy source for the enterocyte, has been shown in animals and adults to prevent mucosal atrophy and deterioration in gut permeability in patients receiving PN. Glutamine administration improves the growth and function of human gut epithe-lial cells.<sup><xref ref-type="bibr" rid="bibr49-0884533613491787">49</xref>,<xref ref-type="bibr" rid="bibr50-0884533613491787">50</xref></sup> PN-dependent individuals, when administered glycyl-glutamine–supplemented PN, demonstrated significantly increased duodenal villous height and decreased intestinal permeability compared with individuals with standard nonsupplemented PN.<sup><xref ref-type="bibr" rid="bibr49-0884533613491787">49</xref></sup> In a large multicenter prospective study, addition of glutamine to the PN of extremely low birth weight neonates (birth weight &lt;1000 g) did not decrease sepsis or shorten the duration of PN use. Parenteral glutamine had no effect on the tolerance of enteral feeds, recurrence of NEC, or growth in these infants.<sup><xref ref-type="bibr" rid="bibr51-0884533613491787">51</xref></sup> In adults, using a combination of enteral glutamine (0.6 g/kg/d), subcutaneously administered human growth hormone, and a high-fiber (apple pectin), low-fat diet (20% fat, 20% protein, and 60% carbohydrate sources) led to improvement of intestinal absorptive capacity and weaning or reducing the need for PN.<sup><xref ref-type="bibr" rid="bibr52-0884533613491787">52</xref></sup> An ongoing, multicenter phase 3 trial to evaluate the safety and efficacy of enteral glutamine in infants with SBS is currently in progress insofar as glutamine is currently not approved for use in pediatrics.</p>
<p>Soluble fiber slows gastric emptying and decreases overall gut transit, resulting in a mild antidiarrheal effect. In the colon, soluble fiber is fermented by bacteria, yielding short-chain fatty acids (butyrate, propionate, and acetate), which serve as an energy source for the colonocytes.<sup><xref ref-type="bibr" rid="bibr53-0884533613491787">53</xref></sup> Short-chain fructo-oligosaccharides are the preferred fiber source as they undergo rapid hydrolysis, which is advantageous in patients with surgical SBS. Short-chain fatty acids also stimulate sodium and water absorption in the colon, thereby decreasing fluid loss.<sup><xref ref-type="bibr" rid="bibr54-0884533613491787">54</xref><xref ref-type="bibr" rid="bibr55-0884533613491787"/>-<xref ref-type="bibr" rid="bibr56-0884533613491787">56</xref></sup> Soluble fiber added to the diet of patients with an intact colon has a significant impact on enteral tolerance.<sup><xref ref-type="bibr" rid="bibr56-0884533613491787">56</xref></sup> This is indicated when feeding advancement is impeded by increased stool loss.</p>
</sec>
<sec id="section5-0884533613491787">
<title>Prevention of CLA-BSIs</title>
<p>Central line care is an important component of the nutrition management of children who require central venous access for long-term PN. This becomes critical if the child is going to need home PN. The educational process of the primary caregivers needs to start as soon as home PN is identified as a possibility. Patient care educators need to evaluate the caregivers with regard to the type of teaching technique that will be used to educate them about caring for the catheter to prevent recurrent CLA-BSIs. The rate of CLA-BSIs reported in this population from a multicenter consortium was 8.9 per 1000 catheter days.<sup><xref ref-type="bibr" rid="bibr7-0884533613491787">7</xref></sup> The rates of home-acquired CLA-BSIs are highest during the first month of home PN and decrease as the caregivers become more knowledgeable and confident with the techniques of appropriately taking care of the line at home.<sup><xref ref-type="bibr" rid="bibr57-0884533613491787">57</xref></sup> The risk for CLA-BSIs was higher in patients from a lower socioeconomic group and if the child was younger than 1 year on discharge.<sup><xref ref-type="bibr" rid="bibr57-0884533613491787">57</xref></sup></p>
<p>The American Pediatric Surgical Association recommends specific strategies outlined in <xref ref-type="table" rid="table3-0884533613491787">Table 3</xref> for preventing recurrent CLA-BSIs.<sup><xref ref-type="bibr" rid="bibr58-0884533613491787">58</xref></sup> These strategies need to be initiated prior to the insertion of the central line and continued as long as the patient has a central venous catheter. As reviewed by the American Pediatric Surgical Association, the use of antimicrobial/antibiotic impregnated catheters has become standard in most institutions when long-term access is required in children.<sup><xref ref-type="bibr" rid="bibr58-0884533613491787">58</xref></sup> Antibiotic and ethanol locks may be recommended in patients with recurrent CLA-BSIs. The use of ethanol lock therapy for preventing CLA-BSIs has been shown to be very effective if used appropriately.<sup><xref ref-type="bibr" rid="bibr59-0884533613491787">59</xref>,<xref ref-type="bibr" rid="bibr60-0884533613491787">60</xref></sup> It is recommended that ethanol lock therapy should be used only with silicone-based catheters as there is evidence suggesting that polyurethane-based catheters are susceptible to breakdown when exposed to ethanol.<sup><xref ref-type="bibr" rid="bibr61-0884533613491787">61</xref></sup> A meta-analysis of 4 small studies has shown that in comparison to heparin locks, ethanol locks reduced CLA-BSIs by 81% and decreased the need to replace lines by 72%.<sup><xref ref-type="bibr" rid="bibr62-0884533613491787">62</xref></sup> Thus, the use of ethanol locks is indicated in children with intestinal failure with a silicone-based catheter who have a previous history of CLA-BSIs and have caregivers who are capable of performing the required care. Antibiotic locks are used less frequently in children compared with adult patients, and more data are needed regarding the type and indication for the use of specific antibiotics as lock therapy in children.</p>
<table-wrap id="table3-0884533613491787" position="float">
<label>Table 3.</label>
<caption>
<p>Recommended Strategies for Preventing Recurrent Central Line–Associated Bloodstream Infections.</p>
</caption>
<graphic alternate-form-of="table3-0884533613491787" xlink:href="10.1177_0884533613491787-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td>Chlorhexidine skin prep and chlorhexidine-impregnated dressing</td>
</tr>
<tr>
<td>Heparin and antibiotic-impregnated central venous catheters</td>
</tr>
<tr>
<td>Ethanol and antibiotic lock therapy</td>
</tr>
<tr>
<td>Chlorhexidine-heparin central venous catheter cap</td>
</tr>
<tr>
<td>Strategic education tools</td>
</tr>
<tr>
<td>Event analysis</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="section6-0884533613491787">
<title>Bacterial Overgrowth</title>
<p>Small bowel bacterial overgrowth is a relatively common problem in patients with surgical SBS.<sup><xref ref-type="bibr" rid="bibr63-0884533613491787">63</xref></sup> Many patients tolerate bacterial overgrowth quite well, and indeed, in some, the anaerobic flora overgrowing the small bowel live in symbiosis with the host, producing short-chain fatty acids that have a caloric value and improve colonic integrity. Furthermore, they acidify the colonic contents, thereby inhibiting the putrefactive gram-negative aerobes, which are prone to translocate across the damaged intestinal lining to produce bloodstream infections.</p>
<p>However, at times, excessive quantities of small bowel bacteria can produce deleterious consequences. In such a case, the patient has small bowel bacterial overgrowth syndrome. The symptoms suggestive of bacterial overgrowth syndrome include feeding intolerance, abdominal distention, gassiness, diarrhea or increased ostomy output, early satiety, or impaired mental status from D-lactic acidosis. The diagnosis is usually made based on symptoms, although occasionally breath hydrogen studies or small bowel aspirates can be obtained to confirm the role of excessive small bowel bacteria in this syndrome.<sup><xref ref-type="bibr" rid="bibr13-0884533613491787">13</xref>,<xref ref-type="bibr" rid="bibr63-0884533613491787">63</xref><xref ref-type="bibr" rid="bibr64-0884533613491787"/>-<xref ref-type="bibr" rid="bibr65-0884533613491787">65</xref></sup> Preventing and treating bacterial overgrowth in these postsurgical patients with injured gut is important for promoting mucosal health and feeding tolerance. Metronidazole is the most popular agent for eradicating anaerobes. This can be used in the context of D-lactic acidosis, whose pathogenesis depends on anaerobic synthesis of D-lactate. It can also be used when the clinician suspects excessive bile salt deconjugation resulting in steatorrhea due to failure of bile acids to achieve a critical micellar concentration in the proximal small bowel. Nitazoxanide and rifaximin also cover obligate anaerobes quite effectively.<sup><xref ref-type="bibr" rid="bibr66-0884533613491787">66</xref>,<xref ref-type="bibr" rid="bibr67-0884533613491787">67</xref></sup> Putrefactive, gram-negative aerobes may be treated with trimethoprim-sulfamethoxazole, aminoglycosides (such as gentamicin) given orally, and extended-spectrum penicillins and cephalosporins. Intermittent monitoring of serum gentamicin levels to avoid ototoxicity and nephrotoxicity may be necessary.<sup><xref ref-type="bibr" rid="bibr68-0884533613491787">68</xref></sup> The use of antibiotics effective against gram-negative flora is especially useful in patients with recurrent gram-negative infections presumably due to translocation of bacteria across the gut. Amoxicillin–clavulanic acid was effective against more than 90% of the isolated species in bacterial overgrowth.<sup><xref ref-type="bibr" rid="bibr69-0884533613491787">69</xref></sup> There are no large-scale clinical trials evaluating the timing and effectiveness of the antibiotics used in this condition. Experts recommend cycling specific antibiotics or antibiotic combinations for 1–2 weeks every month in patients with suspected bacterial overgrowth.<sup><xref ref-type="bibr" rid="bibr64-0884533613491787">64</xref></sup> The improvement in symptoms following therapy is then retrospectively used as evidence for the diagnosis.</p>
</sec>
<sec id="section7-0884533613491787">
<title>Conclusion</title>
<p>Nutrition management of the infant or young child with significant injury to the GI tract that requires resection and long term use of PN is complex. Each patient is unique, and management should be individualized based on the initial injury, amount and site of resection, and duration of PN. Early focus on engaging and educating the primary caregivers is a key predictor for success. Early, aggressive introduction and advancement of enteral feeds are critical for promoting intestinal adaptation, preventing IFALD, and weaning the patient off PN. There is an urgent need for more clinical trials and the establishment of benchmarks that will assist care teams in identifying processes of care that can lead to excellent outcomes.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>Financial disclosures: Conrad R. Cole is supported by National Institutes of Health grant 1R21DK088027-01A1.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0884533613491787">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeppesen</surname><given-names>PB</given-names></name>
</person-group>. <article-title>Clinical significance of GLP-2 in short-bowel syndrome</article-title>. <source>J Nutr</source>. <year>2003</year>;<volume>133</volume>:<fpage>3721</fpage>-<lpage>3724</lpage>.</citation>
</ref>
<ref id="bibr2-0884533613491787">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Milewski</surname><given-names>PJ</given-names></name>
<name><surname>Gross</surname><given-names>E</given-names></name>
<name><surname>Holbrook</surname><given-names>I</given-names></name><etal/>
</person-group>. <article-title>Parenteral nutrition at home in management of intestinal failure</article-title>. <source>BMJ</source>. <year>1980</year>;<volume>280</volume>:<fpage>1356</fpage>-<lpage>1357</lpage>.</citation>
</ref>
<ref id="bibr3-0884533613491787">
<label>3.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Cole</surname><given-names>CR</given-names></name>
<name><surname>Ziegler</surname><given-names>TR</given-names></name>
</person-group>, <article-title>Etiology and epidemiology of intestinal failure</article-title>. In: <person-group person-group-type="editor">
<name><surname>Duggan</surname><given-names>C</given-names></name>
<name><surname>Gura</surname><given-names>K</given-names></name>
<name><surname>Jaksic</surname><given-names>T</given-names></name>
</person-group>, eds. <source>Clinical Management of Intestinal Failure</source>. <publisher-loc>Boca Raton, FL</publisher-loc>: <publisher-name>CRC Press</publisher-name>; <volume>2011</volume>:<fpage>3</fpage>-<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr4-0884533613491787">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>O’Keefe</surname><given-names>SJ</given-names></name>
<name><surname>Buchman</surname><given-names>AL</given-names></name>
<name><surname>Fishbein</surname><given-names>TM</given-names></name><etal/>
</person-group>. <article-title>Short bowel syndrome and intestinal failure: consensus definitions and overview</article-title>. <source>Clin Gastroenterol Hepatol</source>. <year>2006</year>;<volume>4</volume>:<fpage>6</fpage>-<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr5-0884533613491787">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Modi</surname><given-names>BP</given-names></name>
<name><surname>Langer</surname><given-names>M</given-names></name>
<name><surname>Ching</surname><given-names>YA</given-names></name><etal/>
</person-group>. <article-title>Improved survival in a multidisciplinary short bowel syndrome program</article-title>. <source>J Pediatr Surg</source>. <year>2008</year>;<volume>43</volume>:<fpage>20</fpage>-<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr6-0884533613491787">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cole</surname><given-names>CR</given-names></name>
<name><surname>Hansen</surname><given-names>NI</given-names></name>
<name><surname>Higgins</surname><given-names>RD</given-names></name><etal/>
</person-group>. <article-title>Very low birth weight preterm infants with surgical short bowel syndrome: incidence, morbidity and mortality, and growth outcomes at 18 to 22 months</article-title>. <source>Pediatrics</source>. <year>2008</year>;<volume>122</volume>:<fpage>e573</fpage>-<lpage>e582</lpage>.</citation>
</ref>
<ref id="bibr7-0884533613491787">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Squires</surname><given-names>RH</given-names></name>
<name><surname>Duggan</surname><given-names>C</given-names></name>
<name><surname>Teitelbaum</surname><given-names>DH</given-names></name><etal/>
</person-group>. <article-title>Natural history of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure Consortium</article-title>. <source>J Pediatr</source>. <year>2012</year>;<volume>161</volume>:<fpage>723</fpage>-<lpage>728.e2</lpage>.</citation>
</ref>
<ref id="bibr8-0884533613491787">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vu</surname><given-names>LT</given-names></name>
<name><surname>Nobuhara</surname><given-names>KK</given-names></name>
<name><surname>Laurent</surname><given-names>C</given-names></name>
<name><surname>Shaw</surname><given-names>GM</given-names></name>
</person-group>. <article-title>Increasing prevalence of gastroschisis: population-based study in California</article-title>. <source>J Pediatr</source>. <year>2008</year>;<volume>152</volume>:<fpage>807</fpage>-<lpage>811</lpage>.</citation>
</ref>
<ref id="bibr9-0884533613491787">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wilmore</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Factors correlating with a successful outcome following extensive intestinal resection in newborn infants</article-title>. <source>J Pediatr</source>. <year>1972</year>;<volume>80</volume>:<fpage>88</fpage>-<lpage>95</lpage>.</citation>
</ref>
<ref id="bibr10-0884533613491787">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Spencer</surname><given-names>AU</given-names></name>
<name><surname>Kovacevich</surname><given-names>D</given-names></name>
<name><surname>McKinney-Barnett</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Pediatric short-bowel syndrome: the cost of comprehensive care</article-title>. <source>Am J Clin Nutr</source>. <year>2008</year>;<volume>88</volume>:<fpage>1552</fpage>-<lpage>1559</lpage>.</citation>
</ref>
<ref id="bibr11-0884533613491787">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hyman</surname><given-names>PE</given-names></name>
<name><surname>Everett</surname><given-names>SL</given-names></name>
<name><surname>Harada</surname><given-names>T</given-names></name>
</person-group>. <article-title>Gastric acid hypersecretion in short bowel syndrome in infants: association with extent of resection and enteral feeding</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>1986</year>;<volume>5</volume>:<fpage>191</fpage>-<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr12-0884533613491787">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hyman</surname><given-names>PE</given-names></name>
<name><surname>Garvey</surname><given-names>TQ</given-names><suffix>III</suffix></name>
<name><surname>Harada</surname><given-names>T</given-names></name>
</person-group>. <article-title>Effect of ranitidine on gastric acid hypersecretion in an infant with short bowel syndrome</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>1985</year>;<volume>4</volume>:<fpage>316</fpage>-<lpage>319</lpage>.</citation>
</ref>
<ref id="bibr13-0884533613491787">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Youssef</surname><given-names>NN</given-names></name>
<name><surname>Mezoff</surname><given-names>AG</given-names></name>
<name><surname>Carter</surname><given-names>BA</given-names></name>
<name><surname>Cole</surname><given-names>CR</given-names></name>
</person-group>. <article-title>Medical update and potential advances in the treatment of pediatric intestinal failure</article-title>. <source>Curr Gastroenterol Rep</source>. <year>2012</year>;<volume>14</volume>:<fpage>243</fpage>-<lpage>252</lpage>.</citation>
</ref>
<ref id="bibr14-0884533613491787">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cavicchi</surname><given-names>M</given-names></name>
<name><surname>Beau</surname><given-names>P</given-names></name>
<name><surname>Crenn</surname><given-names>P</given-names></name>
<name><surname>Degott</surname><given-names>C</given-names></name>
<name><surname>Messing</surname><given-names>B</given-names></name>
</person-group>. <article-title>Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure</article-title>. <source>Ann Intern Med</source>. <year>2000</year>;<volume>132</volume>:<fpage>525</fpage>-<lpage>532</lpage>.</citation>
</ref>
<ref id="bibr15-0884533613491787">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gura</surname><given-names>KM</given-names></name>
<name><surname>Duggan</surname><given-names>CP</given-names></name>
<name><surname>Collier</surname><given-names>SB</given-names></name><etal/>
</person-group>. <article-title>Reversal of parenteral nutrition–associated liver disease in two infants with short bowel syndrome using parenteral fish oil: implications for future management</article-title>. <source>Pediatrics</source>. <year>2006</year>;<volume>118</volume>:<fpage>e197</fpage>-<lpage>e201</lpage>.</citation>
</ref>
<ref id="bibr16-0884533613491787">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Colomb</surname><given-names>V</given-names></name>
<name><surname>Goulet</surname><given-names>O</given-names></name>
<name><surname>Rambaud</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Long-term parenteral nutrition in children: liver and gallbladder disease</article-title>. <source>Transplant Proc</source>. <year>1992</year>;<volume>24</volume>:<fpage>1054</fpage>-<lpage>1055</lpage>.</citation>
</ref>
<ref id="bibr17-0884533613491787">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gura</surname><given-names>KM</given-names></name>
<name><surname>Lee</surname><given-names>S</given-names></name>
<name><surname>Valim</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Safety and efficacy of a fish-oil–based fat emulsion in the treatment of parenteral nutrition–associated liver disease</article-title>. <source>Pediatrics</source>. <year>2008</year>;<volume>121</volume>:<fpage>e678</fpage>-<lpage>e686</lpage>.</citation>
</ref>
<ref id="bibr18-0884533613491787">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cober</surname><given-names>MP</given-names></name>
<name><surname>Killu</surname><given-names>G</given-names></name>
<name><surname>Brattain</surname><given-names>A</given-names></name><etal/>
</person-group>. <article-title>Intravenous fat emulsions reduction for patients with parenteral nutrition–associated liver disease</article-title>. <source>J Pediatr</source>. <year>2012</year>;<volume>160</volume>:<fpage>421</fpage>-<lpage>427</lpage>.</citation>
</ref>
<ref id="bibr19-0884533613491787">
<label>19.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Kleinman</surname><given-names>RE</given-names></name>
</person-group>. <article-title>Parenteral nutrition</article-title>. In: <source>Pediatric Nutrition Handbook</source>. <edition>6th ed.</edition> <publisher-loc>Elk Grove Village, IL</publisher-loc>: <publisher-name>American Academy of Pediatrics</publisher-name>; <volume>2009</volume>:<fpage>519</fpage>-<lpage>540</lpage>.</citation>
</ref>
<ref id="bibr20-0884533613491787">
<label>20.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Forchielli</surname><given-names>ML</given-names></name>
<name><surname>Miller</surname><given-names>SJ</given-names></name>
</person-group>. <article-title>Nutritional goals and requirements</article-title>. In: <person-group person-group-type="editor">
<name><surname>Merritt</surname><given-names>R</given-names></name>
</person-group>, ed. <source>The A.S.P.E.N. Nutrition Support Practice Manual</source>. <edition>2nd ed.</edition> <publisher-loc>Silver Spring, MD</publisher-loc>: <publisher-name>A.S.P.E.N.</publisher-name>; <volume>2005</volume>:<fpage>38</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr21-0884533613491787">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andorsky</surname><given-names>DJ</given-names></name>
<name><surname>Lund</surname><given-names>DP</given-names></name>
<name><surname>Lillehei</surname><given-names>CW</given-names></name><etal/>
</person-group>. <article-title>Nutritional and other postoperative management of neonates with short bowel syndrome correlates with clinical outcomes</article-title>. <source>J Pediatr</source>. <year>2001</year>;<volume>139</volume>:<fpage>27</fpage>-<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr22-0884533613491787">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quiros-Tejeira</surname><given-names>RE</given-names></name>
<name><surname>Ament</surname><given-names>ME</given-names></name>
<name><surname>Reyen</surname><given-names>L</given-names></name><etal/>
</person-group>. <article-title>Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: a 25-year experience</article-title>. <source>J Pediatr</source>. <year>2004</year>;<volume>145</volume>:<fpage>157</fpage>-<lpage>163</lpage>.</citation>
</ref>
<ref id="bibr23-0884533613491787">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Christie</surname><given-names>DL</given-names></name>
<name><surname>Ament</surname><given-names>ME</given-names></name>
</person-group>. <article-title>Dilute elemental diet and continuous infusion technique for management of short bowel syndrome</article-title>. <source>J Pediatr</source>. <year>1975</year>;<volume>87</volume>:<fpage>705</fpage>-<lpage>708</lpage>.</citation>
</ref>
<ref id="bibr24-0884533613491787">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kollman</surname><given-names>KA</given-names></name>
<name><surname>Lien</surname><given-names>EL</given-names></name>
<name><surname>Vanderhoof</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Dietary lipids influence intestinal adaptation after massive bowel resection</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>1999</year>;<volume>28</volume>:<fpage>41</fpage>-<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr25-0884533613491787">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeppesen</surname><given-names>PB</given-names></name>
<name><surname>Mortensen</surname><given-names>PB</given-names></name>
</person-group>. <article-title>The influence of a preserved colon on the absorption of medium chain fat in patients with small bowel resection</article-title>. <source>Gut</source>. <year>1998</year>;<volume>43</volume>:<fpage>478</fpage>-<lpage>483</lpage>.</citation>
</ref>
<ref id="bibr26-0884533613491787">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joly</surname><given-names>F</given-names></name>
<name><surname>Dray</surname><given-names>X</given-names></name>
<name><surname>Corcos</surname><given-names>O</given-names></name><etal/>
</person-group>. <article-title>Tube feeding improves intestinal absorption in short bowel syndrome patients</article-title>. <source>Gastroenterology</source>. <year>2009</year>;<volume>136</volume>:<fpage>824</fpage>-<lpage>831</lpage>.</citation>
</ref>
<ref id="bibr27-0884533613491787">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vanderhoof</surname><given-names>JA</given-names></name>
<name><surname>Langnas</surname><given-names>AN</given-names></name>
<name><surname>Pinch</surname><given-names>LW</given-names></name>
<name><surname>Thompson</surname><given-names>JS</given-names></name>
<name><surname>Kaufman</surname><given-names>SS</given-names></name>
</person-group>. <article-title>Short bowel syndrome</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>1992</year>;<volume>14</volume>:<fpage>359</fpage>-<lpage>370</lpage>.</citation>
</ref>
<ref id="bibr28-0884533613491787">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dsilna</surname><given-names>A</given-names></name>
<name><surname>Christensson</surname><given-names>K</given-names></name>
<name><surname>Alfredsson</surname><given-names>L</given-names></name>
<name><surname>Lagercrantz</surname><given-names>H</given-names></name>
<name><surname>Blennow</surname><given-names>M</given-names></name>
</person-group>. <article-title>Continuous feeding promotes gastrointestinal tolerance and growth in very low birth weight infants</article-title>. <source>J Pediatr</source>. <year>2005</year>;<volume>147</volume>:<fpage>43</fpage>-<lpage>49</lpage>.</citation>
</ref>
<ref id="bibr29-0884533613491787">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Farrell</surname><given-names>MK</given-names></name>
<name><surname>Balistreri</surname><given-names>WF</given-names></name>
</person-group>. <article-title>Parenteral nutrition and hepatobiliary dysfunction</article-title>. <source>Clin Perinatol</source>. <year>1986</year>;<volume>13</volume>:<fpage>197</fpage>-<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr30-0884533613491787">
<label>30.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Vanderhoof</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Short bowel syndrome</article-title>. In: <person-group person-group-type="editor">
<name><surname>Walker</surname><given-names>JBW</given-names></name>
<name><surname>Duggan</surname><given-names>C</given-names></name>
</person-group>, eds. <source>Nutrition in Pediatrics</source>. <publisher-loc>Hamilton, Canada</publisher-loc>: <publisher-name>Decker</publisher-name>; <volume>2003</volume>:<fpage>772</fpage>-<lpage>789</lpage>.</citation>
</ref>
<ref id="bibr31-0884533613491787">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nightingale</surname><given-names>JM</given-names></name>
<name><surname>Lennard-Jones</surname><given-names>JE</given-names></name>
<name><surname>Gertner</surname><given-names>DJ</given-names></name>
<name><surname>Wood</surname><given-names>SR</given-names></name>
<name><surname>Bartram</surname><given-names>CI</given-names></name>
</person-group>. <article-title>Colonic preservation reduces need for parenteral therapy, increases incidence of renal stones, but does not change high prevalence of gall stones in patients with a short bowel</article-title>. <source>Gut</source>. <year>1992</year>;<volume>33</volume>:<fpage>1493</fpage>-<lpage>1497</lpage>.</citation>
</ref>
<ref id="bibr32-0884533613491787">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DiBaise</surname><given-names>JK</given-names></name>
<name><surname>Young</surname><given-names>RJ</given-names></name>
<name><surname>Vanderhoof</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Intestinal rehabilitation and the short bowel syndrome: part 1</article-title>. <source>Am J Gastroenterol</source>. <year>2004</year>;<volume>99</volume>:<fpage>1386</fpage>-<lpage>1395</lpage>.</citation>
</ref>
<ref id="bibr33-0884533613491787">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vanderhoof</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Short bowel syndrome in children and small intestinal transplantation</article-title>. <source>Pediatr Clin North Am</source>. <year>1996</year>;<volume>43</volume>:<fpage>533</fpage>-<lpage>550</lpage>.</citation>
</ref>
<ref id="bibr34-0884533613491787">
<label>34.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vanderhoof</surname><given-names>JA</given-names></name>
<name><surname>Matya</surname><given-names>SM</given-names></name>
</person-group>. <article-title>Enteral and parenteral nutrition in patients with short-bowel syndrome</article-title>. <source>Eur J Pediatr Surg</source>. <year>1999</year>;<volume>9</volume>:<fpage>214</fpage>-<lpage>219</lpage>.</citation>
</ref>
<ref id="bibr35-0884533613491787">
<label>35.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shulman</surname><given-names>DI</given-names></name>
<name><surname>Hu</surname><given-names>CS</given-names></name>
<name><surname>Duckett</surname><given-names>G</given-names></name>
<name><surname>Lavallee-Grey</surname><given-names>M</given-names></name>
</person-group>. <article-title>Effects of short-term growth hormone therapy in rats undergoing 75% small intestinal resection</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>1992</year>;<volume>14</volume>:<fpage>3</fpage>-<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr36-0884533613491787">
<label>36.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hart</surname><given-names>MH</given-names></name>
<name><surname>Phares</surname><given-names>CK</given-names></name>
<name><surname>Erdman</surname><given-names>SH</given-names></name><etal/>
</person-group>. <article-title>Augmentation of postresection mucosal hyperplasia by plerocercoid growth factor (PGF): analog of human growth hormone</article-title>. <source>Dig Dis Sci</source>. <year>1987</year>;<volume>32</volume>:<fpage>1275</fpage>-<lpage>1280</lpage>.</citation>
</ref>
<ref id="bibr37-0884533613491787">
<label>37.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mainoya</surname><given-names>JR</given-names></name>
</person-group>. <article-title>Influence of ovine growth hormone on water and NaCl absorption by the rat proximal jejunum and distal ileum</article-title>. <source>Comp Biochem Physiol A</source>. <year>1982</year>;<volume>71</volume>:<fpage>477</fpage>-<lpage>479</lpage>.</citation>
</ref>
<ref id="bibr38-0884533613491787">
<label>38.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vanderhoof</surname><given-names>JA</given-names></name>
<name><surname>Kollman</surname><given-names>KA</given-names></name>
<name><surname>Griffin</surname><given-names>S</given-names></name>
<name><surname>Adrian</surname><given-names>TE</given-names></name>
</person-group>. <article-title>Growth hormone and glutamine do not stimulate intestinal adaptation following massive small bowel resection in the rat</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>1997</year>;<volume>25</volume>:<fpage>327</fpage>-<lpage>331</lpage>.</citation>
</ref>
<ref id="bibr39-0884533613491787">
<label>39.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Byrne</surname><given-names>TA</given-names></name>
<name><surname>Morrissey</surname><given-names>TB</given-names></name>
<name><surname>Gatzen</surname><given-names>C</given-names></name><etal/>
</person-group>. <article-title>Anabolic therapy with growth hormone accelerates protein gain in surgical patients requiring nutritional rehabilitation</article-title>. <source>Ann Surg</source>. <year>1993</year>;<volume>218</volume>:<fpage>400</fpage>-<lpage>418</lpage>.</citation>
</ref>
<ref id="bibr40-0884533613491787">
<label>40.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Byrne</surname><given-names>TA</given-names></name>
<name><surname>Persinger</surname><given-names>RL</given-names></name>
<name><surname>Young</surname><given-names>LS</given-names></name>
<name><surname>Ziegler</surname><given-names>TR</given-names></name>
<name><surname>Wilmore</surname><given-names>DW</given-names></name>
</person-group>. <article-title>A new treatment for patients with short-bowel syndrome: growth hormone, glutamine, and a modified diet</article-title>. <source>Ann Surg</source>. <year>1995</year>;<volume>222</volume>:<fpage>243</fpage>-<lpage>255</lpage>.</citation>
</ref>
<ref id="bibr41-0884533613491787">
<label>41.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Byrne</surname><given-names>TA</given-names></name>
<name><surname>Wilmore</surname><given-names>DW</given-names></name>
<name><surname>Iyer</surname><given-names>KR</given-names></name><etal/>
</person-group>. <article-title>Growth hormone, glutamine and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, double-blind, placebo-controlled clinical trial</article-title>. <source>Ann Surg</source>. <year>2005</year>;<volume>242</volume>:<fpage>655</fpage>-<lpage>661</lpage>.</citation>
</ref>
<ref id="bibr42-0884533613491787">
<label>42.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ellegard</surname><given-names>L</given-names></name>
<name><surname>Bosaeus</surname><given-names>I</given-names></name>
<name><surname>Nordgren</surname><given-names>S</given-names></name>
<name><surname>Bengtsson</surname><given-names>BA</given-names></name>
</person-group>. <article-title>Low-dose recombinant human growth hormone increases body weight and lean body mass in patients with short bowel syndrome</article-title>. <source>Ann Surg</source>. <year>1997</year>;<volume>225</volume>:<fpage>88</fpage>-<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr43-0884533613491787">
<label>43.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeppesen</surname><given-names>PB</given-names></name>
<name><surname>Hartmann</surname><given-names>B</given-names></name>
<name><surname>Hansen</surname><given-names>BS</given-names></name><etal/>
</person-group>. <article-title>Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure</article-title>. <source>Gut</source>. <year>1999</year>;<volume>45</volume>:<fpage>559</fpage>-<lpage>563</lpage>.</citation>
</ref>
<ref id="bibr44-0884533613491787">
<label>44.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sigalet</surname><given-names>DL</given-names></name>
<name><surname>Martin</surname><given-names>G</given-names></name>
<name><surname>Meddings</surname><given-names>J</given-names></name>
<name><surname>Hartman</surname><given-names>B</given-names></name>
<name><surname>Holst</surname><given-names>JJ</given-names></name>
</person-group>. <article-title>GLP-2 levels in infants with intestinal dysfunction</article-title>. <source>Pediatr Res</source>. <year>2004</year>;<volume>56</volume>:<fpage>371</fpage>-<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr45-0884533613491787">
<label>45.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drucker</surname><given-names>DJ</given-names></name>
<name><surname>Erlich</surname><given-names>P</given-names></name>
<name><surname>Asa</surname><given-names>SL</given-names></name>
<name><surname>Brubaker</surname><given-names>PL</given-names></name>
</person-group>. <article-title>Induction of intestinal epithelial proliferation by glucagon-like peptide 2</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1996</year>;<volume>93</volume>:<fpage>7911</fpage>-<lpage>7916</lpage>.</citation>
</ref>
<ref id="bibr46-0884533613491787">
<label>46.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>L’Heureux</surname><given-names>MC</given-names></name>
<name><surname>Brubaker</surname><given-names>PL</given-names></name>
</person-group>. <article-title>Therapeutic potential of the intestinotropic hormone, glucagon-like peptide-2</article-title>. <source>Ann Med</source>. <year>2001</year>;<volume>33</volume>:<fpage>229</fpage>-<lpage>235</lpage>.</citation>
</ref>
<ref id="bibr47-0884533613491787">
<label>47.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeppesen</surname><given-names>PB</given-names></name>
<name><surname>Gilroy</surname><given-names>R</given-names></name>
<name><surname>Pertkiewicz</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome</article-title>. <source>Gut</source>. <year>2011</year>;<volume>60</volume>:<fpage>902</fpage>-<lpage>914</lpage>.</citation>
</ref>
<ref id="bibr48-0884533613491787">
<label>48.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jeppesen</surname><given-names>PB</given-names></name>
<name><surname>Pertkiewicz</surname><given-names>M</given-names></name>
<name><surname>Messing</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure</article-title>. <source>Gastroenterology</source>. <year>2012</year>;<volume>143</volume>:<fpage>1473</fpage>-<lpage>1481.e3</lpage>.</citation>
</ref>
<ref id="bibr49-0884533613491787">
<label>49.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van der Hulst</surname><given-names>RR</given-names></name>
<name><surname>van Kreel</surname><given-names>BK</given-names></name>
<name><surname>von Meyenfeldt</surname><given-names>MF</given-names></name><etal/>
</person-group>. <article-title>Glutamine and the preservation of gut integrity</article-title>. <source>Lancet</source>. <year>1993</year>;<volume>341</volume>:<fpage>1363</fpage>-<lpage>1365</lpage>.</citation>
</ref>
<ref id="bibr50-0884533613491787">
<label>50.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ziegler</surname><given-names>TR</given-names></name>
<name><surname>Evans</surname><given-names>ME</given-names></name>
<name><surname>Fernandez-Estivariz</surname><given-names>C</given-names></name>
<name><surname>Jones</surname><given-names>DP</given-names></name>
</person-group>. <article-title>Trophic and cytoprotective nutrition for intestinal adaptation, mucosal repair, and barrier function</article-title>. <source>Annu Rev Nutr</source>. <year>2003</year>;<volume>23</volume>:<fpage>229</fpage>-<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr51-0884533613491787">
<label>51.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Poindexter</surname><given-names>BB</given-names></name>
<name><surname>Ehrenkranz</surname><given-names>RA</given-names></name>
<name><surname>Stoll</surname><given-names>BJ</given-names></name><etal/>
</person-group>. <article-title>Parenteral glutamine supplementation does not reduce the risk of mortality or late-onset sepsis in extremely low birth weight infants</article-title>. <source>Pediatrics</source>. <year>2004</year>;<volume>113</volume>:<fpage>1209</fpage>-<lpage>1215</lpage>.</citation>
</ref>
<ref id="bibr52-0884533613491787">
<label>52.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Byrne</surname><given-names>TA</given-names></name>
<name><surname>Morrissey</surname><given-names>TB</given-names></name>
<name><surname>Nattakom</surname><given-names>TV</given-names></name>
<name><surname>Ziegler</surname><given-names>TR</given-names></name>
<name><surname>Wilmore</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Growth hormone, glutamine, and a modified diet enhance nutrient absorption in patients with severe short bowel syndrome</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1995</year>;<volume>19</volume>:<fpage>296</fpage>-<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr53-0884533613491787">
<label>53.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nordgaard</surname><given-names>I</given-names></name>
<name><surname>Hansen</surname><given-names>BS</given-names></name>
<name><surname>Mortensen</surname><given-names>PB</given-names></name>
</person-group>. <article-title>Importance of colonic support for energy absorption as small-bowel failure proceeds</article-title>. <source>Am J Clin Nutr</source>. <year>1996</year>;<volume>64</volume>:<fpage>222</fpage>-<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr54-0884533613491787">
<label>54.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Byrne</surname><given-names>TA</given-names></name>
<name><surname>Cox</surname><given-names>S</given-names></name>
<name><surname>Karimbakas</surname><given-names>M</given-names></name><etal/>
</person-group>. <article-title>Bowel rehabilitation: an alternative to long-term parenteral nutrition and intestinal transplantation for some patients with short bowel syndrome</article-title>. <source>Transplant Proc</source>. <year>2002</year>;<volume>34</volume>:<fpage>887</fpage>-<lpage>890</lpage>.</citation>
</ref>
<ref id="bibr55-0884533613491787">
<label>55.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ziegler</surname><given-names>TR</given-names></name>
<name><surname>Estivariz</surname><given-names>CF</given-names></name>
<name><surname>Jonas</surname><given-names>CR</given-names></name><etal/>
</person-group>. <article-title>Interactions between nutrients and peptide growth factors in intestinal growth, repair, and function</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>1999</year>;<volume>23</volume>:<fpage>S174</fpage>-<lpage>S183</lpage>.</citation>
</ref>
<ref id="bibr56-0884533613491787">
<label>56.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nordgaard</surname><given-names>I</given-names></name>
<name><surname>Hansen</surname><given-names>BS</given-names></name>
<name><surname>Mortensen</surname><given-names>PB</given-names></name>
</person-group>. <article-title>Colon as a digestive organ in patients with short bowel</article-title>. <source>Lancet</source>. <year>1994</year>;<volume>343</volume>:<fpage>373</fpage>-<lpage>376</lpage>.</citation>
</ref>
<ref id="bibr57-0884533613491787">
<label>57.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mohammed</surname><given-names>A</given-names></name>
<name><surname>Grant</surname><given-names>FK</given-names></name>
<name><surname>Zhao</surname><given-names>VM</given-names></name><etal/>
</person-group>. <article-title>Characterization of posthospital bloodstream infections in children requiring home parenteral nutrition</article-title>. <source>JPEN J Parenter Enteral Nutr</source>. <year>2011</year>;<volume>35</volume>:<fpage>581</fpage>-<lpage>587</lpage>.</citation>
</ref>
<ref id="bibr58-0884533613491787">
<label>58.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>EY</given-names></name>
<name><surname>Chen</surname><given-names>C</given-names></name>
<name><surname>Abdullah</surname><given-names>F</given-names></name><etal/>
</person-group>. <article-title>Strategies for the prevention of central venous catheter infections: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review</article-title>. <source>J Pediatr Surg</source>. <year>2011</year>;<volume>46</volume>:<fpage>2000</fpage>-<lpage>2011</lpage>.</citation>
</ref>
<ref id="bibr59-0884533613491787">
<label>59.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jones</surname><given-names>BA</given-names></name>
<name><surname>Hull</surname><given-names>MA</given-names></name>
<name><surname>Richardson</surname><given-names>DS</given-names></name><etal/>
</person-group>. <article-title>Efficacy of ethanol locks in reducing central venous catheter infections in pediatric patients with intestinal failure</article-title>. <source>J Pediatr Surg</source>. <year>2010</year>;<volume>45</volume>:<fpage>1287</fpage>-<lpage>1293</lpage>.</citation>
</ref>
<ref id="bibr60-0884533613491787">
<label>60.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mouw</surname><given-names>E</given-names></name>
<name><surname>Chessman</surname><given-names>K</given-names></name>
<name><surname>Lesher</surname><given-names>A</given-names></name>
<name><surname>Tagge</surname><given-names>E</given-names></name>
</person-group>. <article-title>Use of an ethanol lock to prevent catheter-related infections in children with short bowel syndrome</article-title>. <source>J Pediatr Surg</source>. <year>2008</year>;<volume>43</volume>:<fpage>1025</fpage>-<lpage>1029</lpage>.</citation>
</ref>
<ref id="bibr61-0884533613491787">
<label>61.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McHugh</surname><given-names>GJ</given-names></name>
<name><surname>Wild</surname><given-names>DJ</given-names></name>
<name><surname>Havill</surname><given-names>JH</given-names></name>
</person-group>. <article-title>Polyurethane central venous catheters, hydrochloric acid and 70% ethanol: a safety evaluation</article-title>. <source>Anaesth Intensive Care</source>. <year>1997</year>;<volume>25</volume>:<fpage>350</fpage>-<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr62-0884533613491787">
<label>62.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Oliveira</surname><given-names>C</given-names></name>
<name><surname>Nasr</surname><given-names>A</given-names></name>
<name><surname>Brindle</surname><given-names>M</given-names></name>
<name><surname>Wales</surname><given-names>PW</given-names></name>
</person-group>. <article-title>Ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: a meta-analysis</article-title>. <source>Pediatrics</source>. <year>2012</year>;<volume>129</volume>:<fpage>318</fpage>-<lpage>329</lpage>.</citation>
</ref>
<ref id="bibr63-0884533613491787">
<label>63.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cole</surname><given-names>CR</given-names></name>
<name><surname>Frem</surname><given-names>J C</given-names></name>
<name><surname>Schmotzer</surname><given-names>B</given-names></name><etal/>
</person-group>. <article-title>The rate of bloodstream infection is high in infants with short bowel syndrome: relationship with small bowel bacterial overgrowth, enteral feeding, and inflammatory and immune responses</article-title>. <source>J Pediatr</source>. <year>2010</year>;<volume>156</volume>:<fpage>941</fpage>-<lpage>947.e1</lpage>.</citation>
</ref>
<ref id="bibr64-0884533613491787">
<label>64.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cole</surname><given-names>CR</given-names></name>
<name><surname>Ziegler</surname><given-names>TR</given-names></name>
</person-group>. <article-title>Small bowel bacterial overgrowth: a negative factor in gut adaptation in pediatric SBS</article-title>. <source>Curr Gastroenterol Rep</source>. <year>2007</year>;<volume>9</volume>:<fpage>456</fpage>-<lpage>462</lpage>.</citation>
</ref>
<ref id="bibr65-0884533613491787">
<label>65.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ziegler</surname><given-names>TR</given-names></name>
<name><surname>Cole</surname><given-names>CR</given-names></name>
</person-group>. <article-title>Small bowel bacterial overgrowth in adults: a potential contributor to intestinal failure</article-title>. <source>Curr Gastroenterol Rep</source>. <year>2007</year>;<volume>9</volume>:<fpage>463</fpage>-<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr66-0884533613491787">
<label>66.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>J</given-names></name>
<name><surname>Lee</surname><given-names>HR</given-names></name>
<name><surname>Low</surname><given-names>K</given-names></name>
<name><surname>Chatterjee</surname><given-names>S</given-names></name>
<name><surname>Pimentel</surname><given-names>M</given-names></name>
</person-group>. <article-title>Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS</article-title>. <source>Dig Dis Sci</source>. <year>2008</year>;<volume>53</volume>:<fpage>169</fpage>-<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr67-0884533613491787">
<label>67.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Majewski</surname><given-names>M</given-names></name>
<name><surname>Reddymasu</surname><given-names>SC</given-names></name>
<name><surname>Sostarich</surname><given-names>S</given-names></name>
<name><surname>Foran</surname><given-names>P</given-names></name>
<name><surname>McCallum</surname><given-names>RW</given-names></name>
</person-group>. <article-title>Efficacy of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small intestinal bacterial overgrowth</article-title>. <source>Am J Med Sci</source>. <year>2007</year>;<volume>333</volume>:<fpage>266</fpage>-<lpage>270</lpage>.</citation>
</ref>
<ref id="bibr68-0884533613491787">
<label>68.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vanderhoof</surname><given-names>JA</given-names></name>
<name><surname>Young</surname><given-names>RJ</given-names></name>
<name><surname>Murray</surname><given-names>N</given-names></name>
<name><surname>Kaufman</surname><given-names>SS</given-names></name>
</person-group>. <article-title>Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome</article-title>. <source>J Pediatr Gastroenterol Nutr</source>. <year>1998</year>;<volume>27</volume>:<fpage>155</fpage>-<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr69-0884533613491787">
<label>69.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quigley</surname><given-names>EMM</given-names></name>
<name><surname>Qiera</surname><given-names>R</given-names></name>
</person-group>. <article-title>Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics</article-title>. <source>Gastroenterology</source>. <year>2006</year>;<volume>130</volume>:<fpage>S78</fpage>-<lpage>S90</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>